Mediterranean diet

The Mediterranean diet (MedDiet) is the most RCT-validated dietary intervention for cardiovascular and aging-relevant outcomes in humans. Originating from the traditional dietary patterns of Mediterranean-basin populations (southern Italy, Greece, Spain), it is characterized by high intake of extra-virgin olive oil (EVOO) as the primary fat, abundant vegetables, legumes, whole grains, fruit, nuts, and fish; moderate consumption of poultry, fermented dairy, and eggs; and low intake of red/processed meat, refined carbohydrates, and sweets. Two landmark RCTs — PREDIMED (primary CV prevention, n≈7,447) and CORDIOPREV (secondary CV prevention, n=1,002) — provide the strongest human-trial evidence, demonstrating significant reductions in composite major cardiovascular events.

Canonical pattern definition

Component	Level	Primary driver
Extra-virgin olive oil	≥4 tbsp/day (PREDIMED protocol)	MUFA (oleic acid C18:1), polyphenols (oleocanthal, hydroxytyrosol)
Vegetables	≥2 servings/meal	Fiber, polyphenols, minerals
Legumes	≥3 servings/week	Fiber, plant protein, resistant starch
Whole grains	At most meals	Fiber, β-glucan
Fruit	≥2 servings/day	Fiber, flavonoids
Nuts	≥3 servings/week (PREDIMED: walnuts emphasized)	PUFA (ALA), MUFA, polyphenols
Fatty fish	≥2–3 servings/week	Long-chain n-3 PUFA (EPA, DHA)
Poultry, dairy (fermented)	Moderate	Protein, calcium
Red wine	≤1 small glass/meal with food (traditional)	Resveratrol, other polyphenols — see alcohol caveats below
Red/processed meat	Low (≤1 serving/week)	Restricts SFA (palmitic, myristic) and heme iron
Refined carbs, sweets, butter	Low	Reduces palmitate + trans-fat exposure

Macronutrient profile (CORDIOPREV intervention arm): ~35–40% fat total (~22% MUFA dominant, ~8% PUFA, ~8–10% SFA), ~40–45% carbohydrate, ~15–20% protein. MUFA:SFA ratio approximately 2.2:1; total unsaturated:saturated approximately 3:1.

Adherence measurement

Two validated instruments are used in clinical trials:

• Mediterranean Diet Score (MDS) — Trichopoulou 1995 instrument; 0–9 scale assigning 1 point each for above-median intakes of nine components. Used in large observational cohorts.
• PREDIMED 14-point screener (MEDAS) — 14-item food frequency checklist developed for PREDIMED. Scores ≥10/14 define “high adherence.” MEDAS adherence shows a steep dose-response in PREDIMED post-hoc analyses. Validated in Spanish and non-Spanish populations. Free-to-use screener; self-administered.

Tier-1 RCT evidence

PREDIMED — original 2013 NEJM and 2018 republication

PREDIMED (Prevención con Dieta Mediterránea) was a Spanish multi-centre RCT (11 sites, encompassing 169 clinics) enrolling 7,447 adults aged 55–80 (men) or 60–80 (women) with high cardiovascular risk (type 2 diabetes or ≥3 CV risk factors) and no CVD at baseline. Three arms: (1) MedDiet supplemented with EVOO (~1 L/week, ≥50 g/day), (2) MedDiet supplemented with mixed nuts (~30 g/day: 15 g walnuts, 7.5 g hazelnuts, 7.5 g almonds), (3) control low-fat advice.

The original 2013 NEJM paper (Estruch et al. 2013, doi:10.1056/NEJMoa1200303 — RETRACTED) ¹ reported a significant primary endpoint reduction (major CV event HR ~0.70 for MedDiet+EVOO, ~0.72 for MedDiet+nuts vs control; ~30% relative risk reduction). The trial was halted early (~4.8 yr median) for efficacy.

The paper was retracted June 2018 because of a data-integrity issue: cluster randomization was applied in some centres but the original analysis treated all participants as individually randomized, inflating precision. The corrected per-protocol/cluster-adjusted analysis was republished as:

Estruch et al. 2018, New England Journal of Medicine — doi:10.1056/NEJMoa1800389 ² — the active citation for PREDIMED claims.

The 2018 republication showed results directionally identical to the original but with wider confidence intervals after the cluster correction. Primary endpoint (myocardial infarction, stroke, or death from cardiovascular causes): in the intention-to-treat analysis adjusted for baseline characteristics and propensity scores, the hazard ratio was 0.69 (95% CI 0.53–0.91) for MedDiet+EVOO and 0.72 (95% CI 0.54–0.95) for MedDiet+nuts vs control — approximately 28–31% relative risk reduction. Both arms retained significance after cluster correction, confirming the core PREDIMED finding.

Key PREDIMED lessons:

• EVOO and nut supplementation were approximately equally protective — MUFA-dominant and PUFA-dominant paths to the Mediterranean pattern both work
• Adherence dose-response was steep: MEDAS scores ≥10 conferred substantially greater protection than lower adherence
• Primary prevention setting (no baseline CVD) confirmed MedDiet reduces de novo events, not just recurrences

CORDIOPREV — secondary prevention vs. low-fat (Lancet 2022)

CORDIOPREV (Coronary Diet Intervention with Olive Oil and Cardiovascular Prevention Study) enrolled 1,002 post-CHD patients (established coronary heart disease) at a single Spanish centre and randomized them to: (1) MedDiet (~35% fat / ~22% MUFA / <8% SFA / ~1.5 L EVOO/week) versus (2) low-fat diet (<30% fat / <10% SFA) for 7 years follow-up ³.

Primary composite endpoint: MI, revascularization, ischemic stroke, peripheral arterial disease, or CV death.

Results: The primary endpoint occurred in 87 participants in the MedDiet group and 111 in the low-fat group (crude rate per 1,000 person-years: 28.1 vs 37.7, log-rank p=0.039). Multivariable-adjusted HRs across models ranged from 0.719 (95% CI 0.541–0.957) to 0.753 (95% CI 0.568–0.998) in favour of the Mediterranean diet — approximately 25–28% relative risk reduction. The effect was more pronounced in men (multiadjusted HR 0.669, 95% CI 0.489–0.915; p=0.013); no significant difference was found in women. The low-fat arm was not a passive control — it was an actively counselled, specifically low-SFA diet — making CORDIOPREV a direct head-to-head between two evidence-based dietary approaches.

The critical CORDIOPREV framing: Reducing SFA below 10% kcal alone (low-fat arm) was less protective than the high-MUFA Mediterranean pattern achieving the same or lower SFA while dramatically raising MUFA. This directly challenges the “any fat = bad” dietary framework and supports the position that fat quality (MUFA/SFA ratio) is the dominant driver, not total fat quantity.

needs-replication — CORDIOPREV was a single-centre Spanish trial; generalizability to non-Mediterranean populations with different baseline diets requires confirmation.

Lyon Diet Heart Study — historical secondary prevention (1994/1999)

Lyon Diet Heart Study by de Lorgeril et al. randomized 605 post-MI patients to a Mediterranean-inspired diet supplemented with an ALA-rich rapeseed (canola) oil margarine (to boost omega-3 ALA without requiring fish oil) versus a “prudent” Western control diet ⁴. Mean follow-up ~46 months.

Results (1999 final publication in Circulation): Three composite outcomes (COs) were studied: CO1 = cardiac death + non-fatal MI (14 events Mediterranean vs 44 control, p=0.0001); CO2 = CO1 plus unstable angina, stroke, heart failure, pulmonary/peripheral embolism (27 vs 90, p=0.0001); CO3 = CO2 plus minor events requiring hospitalisation (95 vs 180, p=0.0002). Adjusted risk ratios ranged from 0.28 to 0.53 across the three composite outcomes. The CO1 risk ratio implies approximately 68% relative risk reduction; the broader CO3 implies approximately 47% reduction. Effect sizes were larger than PREDIMED/CORDIOPREV and statistically striking but the trial was smaller (n=605) and methodologically weaker by modern standards (single-blinding, investigator-assembled dietary supplement, single centre). The ALA-enriched margarine was not a standard Mediterranean food, limiting direct generalizability.

Historical importance: Lyon was the first RCT showing MedDiet could dramatically reduce recurrent cardiac events in secondary prevention; it catalysed the large PREDIMED and CORDIOPREV programs. Lyon’s effect size is likely an overestimate due to smaller sample size + early stopping + less rigorous blinding.

Study	Design	n	Primary prevention?	Median follow-up	HR or RR (composite)	DOI
PREDIMED 2018	Multi-centre RCT (3 arms; 11 sites / 169 clinics)	7,447	Yes	4.8 yr (IQR 2.8–5.8)	HR 0.69 (0.53–0.91) MedDiet+EVOO; 0.72 (0.54–0.95) MedDiet+nuts	doi:10.1056/NEJMoa1800389
CORDIOPREV 2022	Single-centre RCT (2 arms)	1,002	No (post-CHD)	7 yr	HR 0.719–0.753 MedDiet vs low-fat; log-rank p=0.039	doi:10.1016/S0140-6736(22)00122-2
Lyon Diet Heart 1999	Single-centre RCT (2 arms)	605	No (post-MI)	~46 months	Adjusted RR 0.28–0.53 across 3 composite outcomes	doi:10.1161/01.cir.99.6.779

Aging-biomarker evidence

Epigenetic aging — PUFA:SFA ratio and multi-clock deceleration

Bozack et al. 2025 (npj Aging; n=1,771 NHANES adults, complete-case primary analysis) examined dietary fatty acid intakes against eleven epigenetic age-acceleration measures (Horvath1, Horvath2, Hannum, Lin, Zhang, Vidal-Bralo, PhenoAge, GrimAge2, DNAmTL, epiTOC, DunedinPoAm) using NHANES 1999–2002 data ⁵.

• The PUFA:SFA ratio (P:S ratio) was the single strongest dietary-fat predictor of epigenetic aging: each 1-unit increase in P:S ratio (approximating the interquartile range) was associated with −1.05 yr PhenoAge acceleration (95% CI −1.87, −0.22; i.e., lower biological age), and with −0.87 yr lower Horvath1, −0.54 yr lower Horvath2, −0.89 yr lower Hannum. P:S was not significantly associated with GrimAge2, DNAmTL, epiTOC, or DunedinPoAm.
• Total SFA was associated with accelerated GrimAge2 (a mortality biomarker); total PUFA was associated with decelerated first-generation clocks and PhenoAge.
• MUFA associations were heterogeneous across clock types.
• These associations held after adjusting for age, sex, race/ethnicity, BMI, education, occupation, poverty-to-income ratio, smoking, alcohol intake, physical activity, and total energy intake.
• Results were cross-sectional (NHANES 1999–2002); causality not established. Fatty acid intake was estimated from a single 24-hour dietary recall.

This provides the strongest population-level signal linking the Mediterranean dietary-fat signature (high PUFA:SFA) to lower biological age by multi-clock epigenetic measurement. The MUFA:SFA direction was consistent but weaker than PUFA:SFA.

Glycation and GLO1 induction — CORDIOPREV 2024 sub-study

Yubero-Serrano et al. 2024 (CORDIOPREV sub-study, n=809; the 5-year MG/GLO1 readout from the main CORDIOPREV cohort) reported that the Mediterranean-diet arm maintained stable methylglyoxal plasma levels over 5 years while the low-fat arm showed increased MG; GloxI (GLO1) mRNA upregulation in the MedDiet arm correlated with reduced atherosclerosis progression in the post-hoc “non-worsening IMT” subgroup ⁶. This is the first long-duration (5-yr) human RCT evidence for dietary GLO1 induction — earlier evidence was confined to 8-week isolated-polyphenol trials (Rabbani 2021 trans-resveratrol + hesperetin). Caveats: GLO1 measured at mRNA level only (no protein expression or enzyme activity confirmation); the IMT–GLO1 correlation was assessed in a post-hoc subgroup; CORDIOPREV is single-centre Spanish post-CHD only. See cordioprev-2024-meddiet-glo1 for full quantitative detail. needs-replication

Telomere length — PREDIMED-NAVARRA substudy

A substudy of the PREDIMED-NAVARRA cohort (García-Calzón et al. 2016, Clinical Nutrition; doi:10.1016/j.clnu.2016.03.013) found that higher adherence to the Mediterranean diet was associated with longer telomeres in high-cardiovascular-risk subjects ⁷. Association was cross-sectional + prospective within the trial period. Effect magnitude and significance not extracted (primary source PDF not downloaded). needs-replication — single cohort; no other MedDiet RCT has measured telomere length as a pre-specified endpoint.

Mechanistic basis

EVOO polyphenols — NF-κB suppression and COX inhibition

Extra-virgin olive oil polyphenols include:

• Oleocanthal — functions as a natural COX-1/COX-2 inhibitor with ibuprofen-like selectivity profile. Concentrations achievable via dietary EVOO intake (≥4 tbsp/day) produce biologically relevant COX inhibition ⁸. dose-response-unclear — exact COX inhibition at typical dietary doses vs standard NSAID doses not definitively characterized.
• Hydroxytyrosol — activates NRF2, suppresses NF-κB via IκB kinase inhibition, reduces ICAM-1 and E-selectin expression in endothelial cells.
• Oleuropein aglycone — inhibits NLRP3 inflammasome assembly, reducing IL-1β secretion in macrophages.

See nf-kb and nlrp3-inflammasome for pathway detail.

MUFA (oleic acid) — SFA displacement and LDLR preservation

Oleic acid (C18:1, the dominant fatty acid in EVOO and most Mediterranean nuts) replaces palmitic acid (C16:0, the dominant dietary SFA) in membrane phospholipids and metabolic flux. Key differences:

• LDLR regulation: Palmitic acid suppresses LDL receptor (LDLR) expression via the SCAP-INSIG-SREBP-2 axis (lipid sensor → ER retention of SCAP/SREBP-2 → less LDLR transcription → higher plasma LDL). Oleic acid does not trigger this suppression at physiological concentrations, preserving LDLR activity and hepatic LDL clearance. See ldlr, srebp-2, apob.
• ER stress avoidance: Palmitic acid at ≥200 µM causes ER stress via PERK/ATF4/CHOP; oleic acid does not and can rescue palmitate-induced ER stress in co-incubation experiments.
• Membrane fluidity: Incorporation of C18:1 MUFA (one double bond) vs C16:0 SFA increases membrane fluidity in the physiological range, maintaining receptor mobility and signalling capacity with age.

Omega-3 PUFA (EPA, DHA, ALA) — resolvin/protectin synthesis and LDL clearance

Long-chain n-3 PUFAs from fatty fish (EPA C20:5, DHA C22:6) and the plant precursor ALA (C18:3, from walnuts) engage multiple aging-relevant mechanisms:

• Specialized pro-resolving mediators (SPMs): EPA and DHA are precursors for resolvins (Rv), protectins (PD), and maresins (MaR) via 5-LOX and 12/15-LOX pathways. SPMs actively resolve inflammation by programming macrophage efferocytosis and reducing neutrophil recruitment without broad immunosuppression. See spm-pathway.
• PPAR-α activation: EPA/DHA bind and activate peroxisome proliferator-activated receptor alpha (PPAR-α) in the liver, promoting fatty acid β-oxidation and upregulating apolipoprotein A-I (ApoA-I) synthesis — the primary structural protein of HDL.
• SREBP-2 / LDLR co-regulation: PPAR-α activation interacts with SREBP-2 signalling in the liver to upregulate LDLR expression, increasing LDL particle clearance.
• Arachidonic acid (AA) displacement: EPA competes with AA for incorporation into membrane phospholipids, reducing the substrate pool for AA-derived pro-inflammatory eicosanoids (PGE2, LTB4).

needs-replication — ALA-to-EPA/DHA conversion efficiency in humans is low (~5–10%) and variable; walnut-derived ALA may not fully substitute for preformed EPA/DHA from fish in metabolically healthy vs. insulin-resistant individuals.

Fiber — gut microbiome SCFA production and bile acid cycling

Legumes, whole grains, vegetables, and fruits provide ~25–35 g/day dietary fiber in a typical Mediterranean pattern (roughly double the Western average). Two downstream mechanisms:

• SCFA production: Colonic fermentation of prebiotic fibers (inulin, pectin, resistant starch, arabinoxylan) by Bifidobacteria, Lactobacilli, and butyrate-producing Firmicutes generates short-chain fatty acids (butyrate, propionate, acetate). Butyrate is the preferred energy source for colonocytes; propionate and butyrate suppress NF-κB in peripheral immune cells; acetate is a systemic fuel substrate. See dysbiosis for the aging-SCFA connection.
• Bile acid sequestration: Soluble fiber (β-glucan, pectin) sequesters bile acids in the intestinal lumen, reducing enterohepatic recirculation. This depletes the hepatic bile acid pool, derepressing CYP7A1 (cholesterol 7α-hydroxylase) → increased conversion of cholesterol to bile acids → net hepatic cholesterol flux toward LDLR-mediated LDL uptake via SREBP-2 pathway activation.

Reduced palmitic acid exposure — avoiding lipotoxic aging mechanisms

By displacing red meat, butter, and processed foods, the Mediterranean pattern markedly reduces palmitic acid (C16:0) intake. At concentrations achievable via a high-SFA Western diet, palmitate engages:

• NLRP3 inflammasome activation → IL-1β + IL-18 secretion → chronic-inflammation
• ER stress (PERK/ATF4/CHOP) → loss of proteostasis → loss-of-proteostasis
• mTORC1 hyperactivation via lysosomal lipid sensing → autophagy suppression → disabled-macroautophagy
• p16/p21-positive senescence induction in endothelial cells → cellular-senescence

See palmitic-acid for full mechanism detail. The Mediterranean diet’s benefit may partly be the avoidance of these lipotoxic pathways rather than only the provision of protective components.

Aging hallmarks targeted

Hallmark	Primary mechanism	Evidence tier
chronic-inflammation	EVOO polyphenols (NF-κB/COX), PUFA→SPMs, reduced SFA (NLRP3), fiber→SCFA	RCT (hsCRP reduced)
deregulated-nutrient-sensing	Oleic acid preserves LDLR/SREBP-2, PUFA→PPAR-α, improved insulin sensitivity	RCT (fasting insulin, HOMA-IR)
altered-intercellular-communication	Reduced atherogenic ApoB-LDL particle; reduced ICAM-1 / E-selectin; reduced IL-6	RCT (biomarker)
disabled-macroautophagy	Palmitate reduction removes mTOR hyperactivation; fiber→AMPK mild activation	Mechanistic (no direct autophagy flux RCT)
dysbiosis	Fiber-driven Bifidobacteria/butyrate-producers enrichment; polyphenol prebiotic effects	Observational + intervention
cellular-senescence	Palmitate reduction avoids p16+/p21+ endothelial senescence induction	Mechanistic (in-vitro) needs-human-replication
epigenetic-alterations	PUFA:SFA ratio → lower PhenoAge (Bozack 2025, cross-sectional)	Cross-sectional (NHANES)

Recency literature: major recent findings (2021–2026)

This section documents the mandatory R25 recency search (PubMed, 2021–2026 window; meta-analyses, RCTs, systematic reviews).

hsCRP and inflammatory markers (umbrella review): An umbrella review of dietary-pattern meta-analyses on CRP (Tran et al. 2024, British Journal of Nutrition, doi:10.1017/S0007114524001648) found the Mediterranean diet among the most consistently CRP-reducing dietary patterns across interventional and observational meta-analyses, with moderate-to-strong evidence classification ⁹.

Mortality meta-analysis (2026): Nucci et al. 2026 (Nutrition, doi:10.1016/j.nut.2026.113189; PMID 41930792) performed a systematic review and meta-analysis of 54 cohort studies (1,833,267 participants; 346,034 deaths) within the Italian national dietary guidelines synthesis, finding pooled RR for all-cause mortality of 0.96 (95% CI 0.95–0.97) per 1-point increase in Mediterranean diet adherence score (moderate certainty evidence, NUTRIGRADE) ¹⁰. This is post-PREDIMED/CORDIOPREV, cross-validating the primary-prevention endpoint in broader observational literature. needs-replication — meta-analyses of Mediterranean diet and mortality are observational; RCT-level mortality data remain confined to PREDIMED and CORDIOPREV (CV mortality only, not all-cause).

Clinical-trials-active search (2026-05-09): ClinicalTrials.gov v2 API query for “Mediterranean diet” (RECRUITING + ACTIVE_NOT_RECRUITING, countTotal=true) returned 325 active trials. This reflects the breadth of Mediterranean diet research across disease indications (oncology, liver disease, cognitive, cardiovascular, metabolic) — not all are aging-focused. The high trial count indicates a mature intervention with an active mixed-indication research portfolio.

Implementation considerations

Adherence as the dominant moderator

PREDIMED post-hoc analyses show that the protective effect was steeply dose-responsive to MEDAS adherence score. Participants with MEDAS ≥10 vs <10 showed substantially different event rates. Real-world Mediterranean diet adherence is moderate: PREDIMED’s Spanish participants had naturally higher baseline adherence than Northern European or North American populations.

Sodium consideration

Traditional Mediterranean cuisine is not low-sodium — salted fish (anchovies, sardines, capers, olives) are prominent components and can push sodium intake above hypertension guidelines. For hypertensive patients, a MedDiet-DASH hybrid (which enforces low sodium explicitly) may be more appropriate. no-mechanism — the MedDiet+low-sodium combination is not tested in an independent RCT; guidance is extrapolation.

Alcohol — the wine controversy

PREDIMED included allowance for 1 small glass of red wine with meals (traditional Mediterranean pattern). However, recent evidence challenges any cardiovascular benefit of moderate alcohol:

• Stockwell group and associated analyses (multiple 2023–2024 publications) have demonstrated that observational studies showing J-shaped alcohol-cardiovascular curves are substantially biased by inclusion of sick quitters as “abstainers,” inflating apparent benefit at moderate intake.
• Mendelian randomization studies using ADH1B variants as instruments have generally found that genetically predicted alcohol exposure is not cardioprotective and may increase CV risk even at low doses.

Practical interpretation: The Mediterranean dietary pattern can be implemented alcohol-free without losing its primary mechanistic benefits (EVOO, vegetables, legumes, fish, nuts are the active components; wine contributes only at the margins). For patients abstaining from alcohol, the pattern should be framed accordingly. contradictory-evidence — whether wine-inclusive vs wine-free MedDiet has different endpoint outcomes has not been tested in a head-to-head RCT arm.

Cost and access

EVOO (at 4 tbsp/day), fresh fish (2–3×/week), and nuts (≥30 g/day) are more expensive than a Western refined-carbohydrate baseline. Real-world adherence in lower-income populations is limited by food access and cost. Substituting with domestic olive oil (lower polyphenol content than EVOO) or canned sardines/mackerel (high omega-3, lower cost) can partially maintain the pattern at lower cost.

Comparison to other dietary patterns

Pattern	CV-event RCT	Epigenetic-aging data	Mechanism emphasis
Mediterranean	PREDIMED + CORDIOPREV (strong)	Bozack 2025 PUFA:SFA (moderate)	MUFA/PUFA quality; polyphenols; fiber
DASH	Multiple BP-lowering RCTs; no composite CV-event RCT	Limited	Sodium restriction; potassium; fiber
Low-fat	CORDIOPREV low-fat arm (inferior to MedDiet)	None	SFA restriction without MUFA replacement
Ketogenic	No composite CV-event RCT	Limited, short-term	Carbohydrate elimination; ketosis
MIND	Cognitive outcomes; MIND-AD trial (2023) — no primary cognitive endpoint reached at 3 yr	Limited	MedDiet + DASH hybrid, cognitively targeted
Nordic	Smaller observational + short-term RCTs	Minimal	Fatty fish; rapeseed oil; berries; rye

contradictory-evidence — The MIND trial 2023 (JAMA, n=604, 3 yr) did not show significant cognitive benefit of MIND vs. DASH in older adults at risk for Alzheimer’s, partially contradicting earlier observational data. This is a caution against over-extending MedDiet/MIND claims into cognitive endpoints.

Limitations and gaps

• #gap/needs-replication — CORDIOPREV was a single-centre Spanish trial in post-CHD patients. Replication in Northern European or North American populations with different baseline diets is needed.
• #gap/dose-response-unclear — The minimum EVOO volume and specific polyphenol content threshold required for benefit are not established. PREDIMED used ~1 L/week (~4 tbsp/day); lower doses may be less effective.
• #gap/long-term-unknown — Longest RCT follow-up is 7 years (CORDIOPREV). The relationship between MedDiet adherence and all-cause lifespan cannot be established by RCT methodology in any practical timeframe; inference relies on biomarker data.
• #gap/contradictory-evidence — Alcohol-within-MedDiet: modern MR data challenge the wine-protective framing assumed in PREDIMED counselling.
• #gap/needs-human-replication — Palmitate-reduction → senescence avoidance mechanism is established in vitro; no human RCT has measured p16+/p21+ cell burden as a function of SFA vs MUFA substitution.
• #gap/no-mechanism — Whether MedDiet epigenetic-aging deceleration (Bozack 2025) is mediated by the same MUFA/PUFA → SPM / NF-κB mechanism chain or by other unidentified dietary factors is unknown.

Cross-references

• caloric-restriction — MedDiet and CR both reduce chronic inflammation and improve insulin sensitivity via overlapping but distinct mechanisms; MedDiet has stronger RCT evidence at the CV-event level while CR has stronger mechanistic multi-pathway depth
• time-restricted-eating — compatible with MedDiet; circadian alignment of Mediterranean meal timing is an unstudied potential synergy
• ketogenic-diet — mechanistically divergent (high-SFA ketogenic diets conflict with MedDiet’s SFA-reduction principle unless built on EVOO/avocado fat base)
• apob — primary atherogenic particle reduced by MedDiet via LDLR upregulation
• ldlr — forward: LDLR upregulation is the primary mechanism for MedDiet LDL lowering
• srebp-2 — forward: oleic acid preserves SCAP-INSIG-SREBP-2 signalling, maintaining LDLR expression
• palmitic-acid — forward: MedDiet’s benefit is partly avoidance of palmitate’s lipotoxic aging mechanisms
• nf-kb — suppressed by EVOO polyphenols (hydroxytyrosol)
• nlrp3-inflammasome — suppressed by oleuropein aglycone, oleocanthal; also reduced via palmitate displacement
• spm-pathway — forward: EPA/DHA from fatty fish are substrates for anti-inflammatory resolvins and protectins
• chronic-inflammation — primary hallmark targeted
• deregulated-nutrient-sensing — insulin sensitization, LDLR/SREBP-2 preservation
• dysbiosis — fiber-driven SCFA shift; polyphenol prebiotic effect
• atherosclerosis — forward: MedDiet’s primary clinical endpoint is CV event reduction driven by atherosclerosis modification
• cardiovascular-aging — forward: the aging-cardiovascular relevance anchor
• phosphate-additive-reduction — complementary dietary intervention; MedDiet’s whole-food/minimal-processed-food character structurally minimizes inorganic-phosphate-additive intake without making it an explicit target. The two interventions can be combined for additive Klotho-FGF23-axis preservation on top of the MedDiet’s anti-inflammatory + LDL-lowering mechanisms; cross-link to vascular-calcification for the downstream pathology
• vascular-calcification — forward: a partial-but-incomplete MedDiet target; MedDiet reduces intimal calcification via atherosclerosis modification but the medial-calcification pathway requires additional levers (phosphate-additive reduction, MK-7 vit K2)

Footnotes

Footnotes

1. RETRACTED — doi:10.1056/NEJMoa1200303 · Estruch R et al. · NEJM 2013 · “Primary Prevention of Cardiovascular Disease with a Mediterranean Diet” · Retracted June 2018 (retraction doi:10.1056/NEJMc1806491) due to cluster randomization not being accounted for in original analysis. DO NOT cite for quantitative claims. Replaced by the 2018 republication ². Preserved here only to document the historical retraction record; 4,187 citations in OpenAlex as of 2026 are partly to the retracted version. ↩

2. doi:10.1056/NEJMoa1800389 · Estruch R, Ros E, Salas-Salvadó J et al. · NEJM 2018;378:e34 · rct · n=7,447 (EVOO=2,543 / nuts=2,454 / control=2,450) · Spanish multi-centre (11 sites; 169 clinics); 3-arm; high CV risk adults men 55–80 / women 60–80 · primary endpoint: composite MI + stroke + CV death · ITT adjusted HR: 0.69 (95% CI 0.53–0.91) MedDiet+EVOO; 0.72 (95% CI 0.54–0.95) MedDiet+nuts vs control · median follow-up 4.8 yr (IQR 2.8–5.8) · cluster-corrected republication of retracted 2013 paper · local PDF: verified 2026-05-09 · cited 3,230 times (OpenAlex 2026) ↩ ↩²

3. doi:10.1016/S0140-6736(22)00122-2 · Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD et al. · Lancet 2022;399(10338):1876–1885 · PMID 35525255 · rct · n=1,002 (MedDiet=502 / low-fat=500) · post-CHD adults aged 20–75 (secondary prevention); 2-arm (MedDiet ~35% fat/~22% MUFA vs. low-fat <30% fat/<10% SFA) · 7-year follow-up · primary composite: MI + revascularisation + ischaemic stroke + peripheral artery disease + CV death · events: 87 MedDiet vs 111 low-fat; crude rate 28.1 vs 37.7 per 1,000 person-years; log-rank p=0.039 · multivariable-adjusted HR range 0.719 (0.541–0.957) to 0.753 (0.568–0.998) · single-centre (Córdoba, Spain) · not OA; verified against PubMed abstract 2026-05-09 · cited 521 times (OpenAlex 2026) ↩

4. doi:10.1161/01.cir.99.6.779 · de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N · Circulation 1999;99(6):779–785 · PMID 9989963 · rct · n=605 · post-MI adults (secondary prevention); 2-arm (Mediterranean + ALA-enriched canola margarine vs “prudent” Western diet); mean follow-up ~46 months · CO1 (cardiac death + non-fatal MI): 14 vs 44 events (p=0.0001); CO2 (+unstable angina/stroke/heart failure/embolism): 27 vs 90 (p=0.0001); CO3 (+minor events): 95 vs 180 (p=0.0002) · adjusted risk ratios ranged from 0.28 to 0.53 across three composite outcomes · not OA; verified against PubMed abstract 2026-05-09 · cited 2,887 times (OpenAlex 2026) ↩

5. doi:10.1038/s41514-025-00298-x · Bozack AK, Khodasevich D, Nwanaji-Enwerem JC, Gladish N, Shen H, Daredia S, Needham BL, Rehkopf DH, Guasch-Ferré M, Cardenas A · npj Aging 2026;12:3 · observational (cross-sectional) · n=1,771 NHANES US adults (complete-case primary analysis; N=2,260 total) · NHANES 1999–2002 · eleven epigenetic aging biomarkers (Horvath1, Horvath2, Hannum, Lin, Zhang, Vidal-Bralo, PhenoAge, GrimAge2, DNAmTL, epiTOC, DunedinPoAm) · PUFA:SFA (P:S) ratio = strongest dietary-fat predictor: 1-unit increase → −1.05 yr PhenoAge (95% CI −1.87, −0.22); also −0.87 yr Horvath1, −0.54 yr Horvath2, −0.89 yr Hannum · adjusted for age, sex, race/ethnicity, BMI, education, occupation, income ratio, smoking, alcohol, physical activity, total energy · fatty acid intake from single 24-hr dietary recall · model: human cross-sectional · local PDF: verified 2026-05-09 ↩

6. doi:10.1186/s12933-024-02451-4 · Gutierrez-Mariscal FM, Lopez-Moreno A, Torres-Peña JD et al. (CORDIOPREV; senior Lopez-Miranda J) · Cardiovasc Diabetol 2024;23(1):361 · PMID 39402581 · rct sub-study · n=809 (193 excluded for incomplete imaging from CORDIOPREV main cohort n=1,002) · 5-year follow-up · MedDiet maintained stable plasma MG vs low-fat arm increase; GLO1 mRNA upregulation in MedDiet correlated with reduced IMT progression in post-hoc non-worsening-IMT subgroup · model: human secondary-prevention CHD · OA gold via PMC11475769; DOI lookup pending · post-hoc-subgroup mrna-only-readout ↩

7. doi:10.1016/j.clnu.2016.03.013 · García-Calzón S, Gea A, Razquin C et al. · Clinical Nutrition 2016;35(6):1399–1405 · observational (prospective cohort within PREDIMED-NAVARRA) · n=520 high-CV-risk adults · MDS adherence associated with longer telomeres at baseline and attenuated telomere shortening over ~5 yr · cross-sectional and prospective association; not a telomere-as-primary-endpoint RCT · model: human · OA green (dadun.unav.edu); local PDF pending · cited 97 times ↩

8. Oleocanthal COX inhibition at dietary EVOO doses: mechanistic data from Beauchamp GK et al. Nature 2005;437:45–46 (doi:10.1038/437045a); quantitative comparison of ibuprofen vs oleocanthal COX inhibition potency and the dose-equivalence calculation (≈9 ibuprofen doses per day of EVOO) was from that letter. Dose-response at the population adherence level (2–4 tbsp EVOO) not formally established. dose-response-unclear ↩

9. doi:10.1017/S0007114524001648 · Tran NQ et al. · British Journal of Nutrition 2024 · umbrella review of meta-analyses (interventional + observational) on dietary patterns and circulating CRP in adults · Mediterranean diet among most consistently CRP-reducing dietary patterns; effect sizes and certainty grading available in source (not extracted into wiki) · model: human · OA bronze ↩

10. doi:10.1016/j.nut.2026.113189 · Nucci D et al. (Mediterranean Diet Guideline Group) · Nutrition 2026;147:113189 · PMID 41930792 · systematic review + meta-analysis · 54 cohort studies; 1,833,267 participants; 346,034 deaths · pooled RR for all-cause mortality: 0.96 (95% CI 0.95–0.97) per 1-point increase in MD adherence score · certainty of evidence: moderate (NUTRIGRADE) · model: human observational ↩